Patents by Inventor Jeff Castelli

Jeff Castelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Fabry disease in ERT-naïve and ERT-experienced patients
    Patent number: 12599594
    Abstract: Provided are dosing regimens for the treatment of Fabry disease in a patient. Certain methods relate to the treatment of ERT-experienced or ERT-naïve Fabry patients. Certain methods comprise administering to the patient about 123 mg free base equivalent of migalastat for improving left ventricular mass and/or improving podocyte globotriaosylceramide.
    Type: Grant
    Filed: May 18, 2023
    Date of Patent: April 14, 2026
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Jeff Castelli
  • Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
    Patent number: 12599595
    Abstract: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.
    Type: Grant
    Filed: May 18, 2023
    Date of Patent: April 14, 2026
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, David J. Lockhart
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20260097027
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: April 21, 2025
    Publication date: April 9, 2026
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods for Treating Pompe Disease
    Publication number: 20260041744
    Abstract: Provided herein are methods for treating Pompe disease by administering to a subject a population of recombinant human acid ?-glucosidase molecules or a pharmaceutical composition or formulation thereof, and an enzyme stabilizer.
    Type: Application
    Filed: May 5, 2023
    Publication date: February 12, 2026
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jay Barth, Sheela Sitaraman Das, Jeff Castelli
  • Methods of treating fabry patients having renal impairment
    Patent number: 12280042
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: April 22, 2025
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 12109205
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: October 8, 2024
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Treatment of Fabry disease in ERT-naïve and ERT-experienced patients
    Patent number: 12070453
    Abstract: Provided are dosing regimens for the treatment of Fabry disease in a patient. Certain methods relate to the treatment of ERT-experienced or ERT-nave Fabry patients. Certain methods comprise administering to the patient about 123 mg free base equivalent of migalastat for improving left ventricular mass and/or improving podocyte globotriaosylceramide.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: August 27, 2024
    Assignee: Amicus Therapeutics, Inc.
    Inventor: Jeff Castelli
  • Methods of treating Fabry patients having renal impairment
    Patent number: 12042489
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: May 31, 2023
    Date of Patent: July 23, 2024
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 12042488
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: May 31, 2023
    Date of Patent: July 23, 2024
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 12042490
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: May 31, 2023
    Date of Patent: July 23, 2024
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20240122911
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: May 31, 2023
    Publication date: April 18, 2024
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11903938
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: February 20, 2024
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20230381165
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: May 31, 2023
    Publication date: November 30, 2023
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20230381164
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: May 31, 2023
    Publication date: November 30, 2023
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11826360
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: November 28, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
    Publication number: 20230364071
    Abstract: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.
    Type: Application
    Filed: May 18, 2023
    Publication date: November 16, 2023
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, David J. Lockhart
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11813255
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: November 14, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 11786516
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: October 17, 2023
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Treatment Of Fabry Disease In ERT-Naïve And ERT-Experienced Patients
    Publication number: 20230321065
    Abstract: Provided are dosing regimens for the treatment of Fabry disease in a patient. Certain methods relate to the treatment of ERT-experienced or ERT-naïve Fabry patients. Certain methods comprise administering to the patient about 123 mg free base equivalent of migalastat for improving left ventricular mass and/or improving podocyte globotriaosylceramide.
    Type: Application
    Filed: May 18, 2023
    Publication date: October 12, 2023
    Applicant: Amicus Therapeutics, Inc.
    Inventor: Jeff Castelli
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20230218599
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: December 21, 2022
    Publication date: July 13, 2023
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin